Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Q1 2024 value amounting to $116.8 million.

  • Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1065.25% to $116.8 million in Q1 2024 from the same period last year, while for Mar 2024 it was $116.8 million, marking a year-over-year increase of 1065.25%. This contributed to the annual value of $106.3 million for FY2023, which is 281.03% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Shares Outstanding (Weighted Average) of $116.8 million as of Q1 2024, which was up 1065.25% from $106.3 million recorded in Q4 2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $116.8 million during Q1 2024, and its lowest value of $102.8 million during Q1 2022.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $103.5 million (recorded in 2020), while the average stood at $104.8 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) tumbled by 99.5% in 2022 and then soared by 1065.25% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $103.5 million in 2020, then fell by 0.13% to $103.4 million in 2021, then decreased by 0.0% to $103.4 million in 2022, then rose by 2.81% to $106.3 million in 2023, then rose by 9.9% to $116.8 million in 2024.
  • Its last three reported values are $116.8 million in Q1 2024, $106.3 million for Q4 2023, and $106.6 million during Q3 2023.